GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gala Pharmaceutical Inc (OTCPK:GLPH) » Definitions » Piotroski F-Score

Gala Pharmaceutical (Gala Pharmaceutical) Piotroski F-Score : 0 (As of May. 11, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Gala Pharmaceutical Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Gala Pharmaceutical has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Gala Pharmaceutical's Piotroski F-Score or its related term are showing as below:


Gala Pharmaceutical Piotroski F-Score Historical Data

The historical data trend for Gala Pharmaceutical's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gala Pharmaceutical Piotroski F-Score Chart

Gala Pharmaceutical Annual Data
Trend Nov11 Nov12 Nov13 Nov14 Nov15 Nov16 Nov17 Nov18
Piotroski F-Score
Get a 7-Day Free Trial N/A N/A N/A 3.00 6.00

Gala Pharmaceutical Quarterly Data
Aug14 Nov14 Feb15 May15 Aug15 Nov15 Feb16 May16 Aug16 Nov16 Feb17 May17 Aug17 Nov17 Feb18 May18 Aug18 Nov18 Feb19 May19
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 5.00 6.00 5.00 2.00

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (May19) TTM:Last Year (May18) TTM:
Net Income was -0.712 + -0.17 + -0.577 + -2.113 = $-3.57 Mil.
Cash Flow from Operations was -0.1 + -0.289 + -0.108 + -0.099 = $-0.60 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of this year (May18)
to the end of this year (May19) was
(0.266 + 0.248 + 0.262 + 0.283 + 0.386) / 5 = $0.289 Mil.
Total Assets at the begining of this year (May18) was $0.27 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $0.09 Mil.
Total Current Liabilities was $3.46 Mil.
Net Income was -0.695 + -0.882 + -0.583 + -0.394 = $-2.55 Mil.

Revenue was 0 + 0 + 0 + 0.005 = $0.01 Mil.
Gross Profit was 0 + 0 + 0 + 0.001 = $0.00 Mil.
Average Total Assets from the begining of last year (May17)
to the end of last year (May18) was
(0.359 + 0.361 + 0.108 + 0.321 + 0.266) / 5 = $0.283 Mil.
Total Assets at the begining of last year (May17) was $0.36 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $0.23 Mil.
Total Current Liabilities was $0.97 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Gala Pharmaceutical's current Net Income (TTM) was -3.57. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Gala Pharmaceutical's current Cash Flow from Operations (TTM) was -0.60. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (May18)
=-3.572/0.266
=-13.42857143

ROA (Last Year)=Net Income/Total Assets (May17)
=-2.554/0.359
=-7.11420613

Gala Pharmaceutical's return on assets of this year was -13.42857143. Gala Pharmaceutical's return on assets of last year was -7.11420613. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Gala Pharmaceutical's current Net Income (TTM) was -3.57. Gala Pharmaceutical's current Cash Flow from Operations (TTM) was -0.60. ==> -0.60 > -3.57 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: May19)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from May18 to May19
=0/0.289
=0

Gearing (Last Year: May18)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from May17 to May18
=0/0.283
=0

Gala Pharmaceutical's gearing of this year was 0. Gala Pharmaceutical's gearing of last year was 0. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: May19)=Total Current Assets/Total Current Liabilities
=0.093/3.464
=0.02684758

Current Ratio (Last Year: May18)=Total Current Assets/Total Current Liabilities
=0.225/0.967
=0.23267839

Gala Pharmaceutical's current ratio of this year was 0.02684758. Gala Pharmaceutical's current ratio of last year was 0.23267839. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Gala Pharmaceutical's number of shares in issue this year was 103.643. Gala Pharmaceutical's number of shares in issue last year was 53.205. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0/0
=

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0.001/0.005
=0.2

Gala Pharmaceutical's gross margin of this year was . Gala Pharmaceutical's gross margin of last year was 0.2. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (May18)
=0/0.266
=0

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (May17)
=0.005/0.359
=0.01392758

Gala Pharmaceutical's asset turnover of this year was 0. Gala Pharmaceutical's asset turnover of last year was 0.01392758. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+1+0+0+0+0
=2

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Gala Pharmaceutical has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

Gala Pharmaceutical  (OTCPK:GLPH) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Gala Pharmaceutical Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Gala Pharmaceutical's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Gala Pharmaceutical (Gala Pharmaceutical) Business Description

Traded in Other Exchanges
N/A
Address
18881 Von Karman Avenue, Suite 1440, Irvine, CA, USA, 92612
Gala Pharmaceutical Inc is a United States-based company engaged in the hemp and cannabidiol (CBD) industry. It is focused on the development, research, and commercialization of products derived from the hemp and cannabis plant. It is focused on CBD flavored thin-film strip which is an advanced method of providing CBD for the dietary supplement. The services offered by the company are the development of cannabinoid-based health and wellness products; development of medical grade compounds; licensing of proprietary testing, genetics, labeling and packaging, tracking, production, and standardization methods for the medicinal herb industry. The group earns revenue from the sale of products related to hemp and CBD, including modified electronic cigarettes and vape pens.